In randomized trials in humans, subcutaneous elamipretide increased mild-moderate injection site-related events.
In plain wordsIn trials in people, elamipretide injected under the skin caused more mild to moderate injection site events.
- Peptide
- Elamipretide (SS-31)
- Outcome
- IncreaseInjection site-related events
- Study
n: not reported in source
- Outcome group
- Adverse events · Whole body
- Studied dose
- Dose not stated · subcutaneousAs given in this study (human).
Source sentences
although subcutaneous injection of Elamipretide increased mild-moderate injection site-related events
1 context sentence(design, population, supporting numbers)
Nineteen studies (n = 884 participants) using mitoAOXs (including Elamipretide, MitoQ and MitoTEMPO) were included in the systematic review.